A 4-aminobenzoic acid derivative as novel lead for selective inhibitors of multidrug resistance-associated proteins

Bioorg Med Chem Lett. 2008 Sep 1;18(17):4761-3. doi: 10.1016/j.bmcl.2008.07.127. Epub 2008 Aug 3.

Abstract

We present a novel lead for inhibitors of multidrug resistance-associated proteins (MRPs). Compound 1 (4-[(5,6,7,8-tetrahydro-4-oxo-4H-[1]benzothieno[2,3-d][1,3]thiazin-2-yl)amino]benzoic acid) was about six times more potent than the known inhibitor MK571 at MRP1, while at MRP2 its effect was similar to that of MK571. Structural analogs were also evaluated. Among them, compound 2, sharing the 4-aminobenzoic acid substructure with 1, also inhibited MRP1. Both derivatives were inactive against P-gp. It can be concluded that their carboxyl group is needed for inhibition of MRPs and accounts for the selectivity of these compounds.

Publication types

  • Comparative Study

MeSH terms

  • 4-Aminobenzoic Acid / chemistry
  • 4-Aminobenzoic Acid / pharmacology*
  • Animals
  • Cell Line
  • Cell Line, Tumor
  • Dogs
  • Drug Resistance, Multiple / drug effects
  • Humans
  • Multidrug Resistance-Associated Protein 2
  • Multidrug Resistance-Associated Proteins / antagonists & inhibitors*
  • Multidrug Resistance-Associated Proteins / pharmacology
  • Thiazines / chemistry
  • Thiazines / pharmacology*
  • para-Aminobenzoates*

Substances

  • 4-((5,6,7,8-tetrahydro-4-oxo-4H-(1)benzothieno(2,3-d)(1,3)thiazin-2-yl)amino)benzoic acid
  • ABCC2 protein, human
  • Multidrug Resistance-Associated Protein 2
  • Multidrug Resistance-Associated Proteins
  • Thiazines
  • para-Aminobenzoates
  • 4-Aminobenzoic Acid
  • multidrug resistance-associated protein 1